AZD5004 for Drug Interaction Study in Healthy Subjects
Trial Summary
What is the purpose of this trial?
This study will assess the effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the effect of Erythromycin on AZD5004 in healthy adult male and female participants.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, since the study involves drug interactions, it's possible that some medications might need to be paused. Please consult with the trial coordinators for specific guidance.
Is AZD5004 (azithromycin) safe for humans?
Eligibility Criteria
This clinical trial is for healthy adult men and women. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and not have conditions that could interfere with the study or pose a risk.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment Part A
Participants receive rosuvastatin and AZD5004, and later erythromycin in multiple treatment periods
Follow-up Part A
Participants are monitored for safety and effectiveness after treatment
Treatment Part B
Participants receive atorvastatin, simvastatin, and AZD5004 in multiple treatment periods
Follow-up Part B
Participants are monitored for safety and effectiveness after treatment
Treatment Part C
Participants receive repaglinide and AZD5004 in multiple treatment periods
Follow-up Part C
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- AZD5004
- Erythromycin
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology